News | Atherectomy Devices | March 09, 2022

Class I Recall on TurboHawk Plus Directional Atherectomy System by Medtronic

Recall is due to risk of tip damage during use

Medtronic is recalling (correcting) the TurboHawk Plus Directional Atherectomy System due to design similarities shared with another device that was recently recalled for correction.

March 9, 2022 — Medtronic is recalling (correcting) the TurboHawk Plus Directional Atherectomy System due to design similarities shared with another device that was recently recalled for correction. There is a risk of the guidewire within the catheter moving downward or prolapsing when force is applied during use. If this happens, the catheter tip may break off or separate and this could lead to serious adverse events including a tear along the inside wall of an artery (arterial dissection), a rupture or breakage of an artery (arterial rupture), decrease in blood flow to a part of the body because of a blocked artery (ischemia), and/or blood vessel complications that could require surgical repair and additional procedures to capture and remove the detached and/or migrated (embolized) tip.

As of February 7, 2022, there have been no reported injuries or deaths associated with this problem. 

For more information about this recall.

BACKGROUND: The TurboHawk Plus Directional Atherectomy System consists of a catheter and a cutter driver. This device is used during procedures intended to remove blockage from peripheral arteries and improve blood flow.

RECOMMENDATIONS: On February 4, 2022, Medtronic sent all affected customers an Urgent Medical Device Notice requesting they take the following actions:   

  • Be aware, there are no product retrievals or disposals requested by Medtronic.
  • Share Notice with all those who need to be aware within your organization or to any organization where the products have been transferred.
  • Customers who have questions about this recall should contact the company. 

Health professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program:

  • Complete and submit the report online.
  • Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on form, or submit by fax to 1-800-FDA-0178.

For more information: www.fda.gov


Related Content

News | Cath Lab

May 13, 2026 — According to a recently released report, the global cath lab services market was valued at $46.0 billion ...

Home May 13, 2026
Home
News | Cath Lab

April 16, 2026 — A national study led by investigators from Cedars-Sinai Health Sciences University found that ...

Home April 20, 2026
Home
News | Cath Lab

April 6, 2026 —Stereotaxis has received U.S. Food and Drug Administration 510(k) clearance for its Synchrony system ...

Home April 07, 2026
Home
News | Cath Lab

March 31, 2026 — Solo Pace Inc. has announced the commercial release of the SoloPace Fusion Temporary Pacing System. The ...

Home April 03, 2026
Home
News | Cath Lab

March 25, 2026 — Royal Philips has launched its intuitive interventional guidance platform, IntraSight Plus, which is ...

Home March 26, 2026
Home
Feature | Cath Lab | Kyle Hardner

Since receiving FDA approval in 2016, intravascular lithotripsy (IVL) systems have grown in popularity among ...

Home November 14, 2025
Home
News | Cath Lab

Nov. 11, 2025 — FastWave Medical has successfully completed enrollment in its 30-patient coronary feasibility study and ...

Home November 13, 2025
Home
News | Cath Lab

Oct. 28, 2025 — Results from the first-of-its-kind randomized PROCTOR trial found that a strategy of saphenous vein ...

Home November 04, 2025
Home
News | Cath Lab

Oct. 27, 2025 — Results from the PREVUE-VALVE study suggest that there are currently at least 4.7 million people aged 65 ...

Home October 29, 2025
Home
News | Cath Lab

Oct. 25, 2025 — Medtronic plc has announced the launch of the Stedi Extra Support guidewire, designed to enhance ...

Home October 28, 2025
Home
Subscribe Now